Critical Pharmaceuticals and The University of Nottingham to Develop Nano-Enabled Nasal Spray for Osteoporosis

The Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) provide grant funding to support the £545,000 project

21-Feb-2012 - United Kingdom

Critical Pharmaceuticals and The University of Nottingham today announce a £545,000 collaboration to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis.

Teriparatide, an excellent recent addition to the range of drugs used for the treatment of osteoporosis, but it currently needs to be injected every day. Our consortium will exploit a recent discovery in nanotechnology to develop a nasal spray formulation of teriparatide that is easy to administer by patients and provides optimal drug plasma levels to enhance efficacy.

The Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) are supporting this project with grant funding as part of their investment in nanoscale technology-enabled solutions in healthcare.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances